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Abstract
Reliable behavioural tests in animal models of neurodegenerative diseases allow us to study the natural history of disease
and evaluate the efficacy of novel therapies. Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo A), is a severe,
neurodegenerative lysosomal storage disorder caused by a deficiency in the heparan sulphate catabolising enzyme,
sulfamidase. Undegraded heparan sulphate accumulates, resulting in lysosomal enlargement and cellular dysfunction.
Patients suffer a progressive loss of motor and cognitive function with severe behavioural manifestations and premature
death. There is currently no treatment. A spontaneously occurring mouse model of the disease has been described, that has
approximately 3% of normal enzyme activity levels. Behavioural phenotyping of the MPS IIIA mouse has been previously
reported, but the results are conflicting and variable, even after full backcrossing to the C57BL/6 background. Therefore we
have independently backcrossed the MPS IIIA model onto the C57BL/6J background and evaluated the behaviour of male
and female MPS IIIA mice at 4, 6 and 8 months of age using the open field test, elevated plus maze, inverted screen and
horizontal bar crossing at the same circadian time point. Using a 60 minute open field, we have demonstrated that female
MPS IIIA mice are hyperactive, have a longer path length, display rapid exploratory behaviour and spend less time immobile
than WT mice. Female MPS IIIA mice also display a reduced sense of danger and spend more time in the centre of the open
field. There were no significant differences found between male WT and MPS IIIA mice and no differences in neuromuscular
strength were seen with either sex. The altered natural history of behaviour that we observe in the MPS IIIA mouse will allow
more accurate evaluation of novel therapeutics for MPS IIIA and potentially other neurodegenerative disorders.
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Introduction
Mucopolysaccharidosis IIIA (MPS IIIA, OMIM #252900), or
Sanfilippo Type A, is an autosomal recessive lysosomal storage
disorder that affects 0.82 in 100,000 live births in the United
Kingdom [1]. The disease is characterised by severe and
progressive loss of cognitive and motor functions, behavioural
difficulties and eventually death in the second decade of life,
although the severity and progression of the disease varies widely
[1,2,3]. MPS IIIA is caused by mutations in the SGSH gene that
result in deficiency of the N-sulfoglucosamine sulfohydrolase
enzyme (sulfamidase, EC 3.10.1.1) and subsequent accumulation
of undegraded heparan sulphate, lysosomal enlargement and
cellular and organ dysfunction [4,5,6,7]. Patients exhibit progres-
sive neurodegeneration and behavioural problems including
hyperactivity, a reduced sense of danger, aggression and sleep
disturbances [7,8,9,10,11,12].
Although there are no current therapies, several strategies are
in development for MPS IIIA or the phenotypically indistin-
guishable MPS IIIB disease, including substrate reduction
therapy [13,14,15], intrathecal enzyme replacement therapy
[16,17,18,19,20] and gene therapy with lentiviral [21], adenoviral
[22] or adeno-associated-viral [23] vectors. Most strategies make
use of the ability of exogenous enzyme to complement affected
cells, however the presence of the blood brain barrier limits
efficient enzyme distribution. Biomarkers for MPS IIIA or related
diseases are still in development [24,25], thus the accurate
evaluation of neurodegeneration using behavioural phenotyping
in the mouse model of disease is paramount. A spontaneously
occurring mouse model of MPS IIIA on a mixed 129SvJ,
C57BL/6, SJL, and CD1 background has been previously
described with around 3% of normal enzyme activity and
exhibiting many of the features observed in patients [26]. The
MPS IIIA mice exhibit severe neuropathology characterised by
enlarged lysosomes, primary storage of HS, secondary storage of
GM2 and GM3 gangliosides and cholesterol and chronic
neuroinflammation [19,23,26,27,28]. The MPS IIIA mice are
euthanized between 9 and 12 months of age due to urine
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MPS IIIB mice [29]. The MPS IIIA mouse model has been
backcrossed to the C57BL/6 background by Professor John
Hopwood’s Lysosomal Diseases Research Unit [30] and to the
C57BL/6J background by Jackson laboratories [31].
Although the behaviour of the MPS IIIA mouse model has been
evaluated in the open field test at several ages, using different
sexes, by several groups and on different strain backgrounds, there
is a remarkable amount of variability in the outcome of the test as
outlined in Table 1.
Using the mixed background mouse, at many of the time points
measured, no differences are observed between either male or
female WT and MPS IIIA mice, with initial findings of
hyperactivity and later hypoactivity in males [18,32]. After back
crossing the MPS IIIA mice on to a C57BL/6 background, the
behaviour was extensively studied by Crawley et al. at different
time points. Hyperactivity in males was observed at 12 weeks of
age, and females at 22 and 32 weeks of age, although these mice
were not naively tested [30]. At most time points, no differences
were seen. However male, but not female, MPS IIIA mice were
shown to be hypoactive at some time points in the work of Lau et al
[33] and male MPS IIIA mice were hypoactive at 15 weeks of age
in a more recent paper by Lau et al. [34]. Hypoactivity in male
mice was also observed at some time points in McIntyre et al. [21].
In columns 7, 8, 9 and 10 of Table 1 (marked as bold) we have also
presented markedly variable outcomes of observations of locomo-
tor behaviour of MPS IIIA and WT mice that received control
intracranial injections [18,21,23,35].
Patients with MPS IIIA are believed to have a reduced sense of
danger, which can be inferred in mice by the amount of time spent
in the centre of the open field test or by use of the elevated plus
maze test, both of which can be used to measure their tendency to
avoid open spaces and remain close to cover (thigmotaxis). No
difference in the time in centre of the open field was detected by
Lau et al. [33], however this could be due to the small size of the
open field used. In the elevated plus maze, male MPS IIIA mice
were reported to display reduced anxiety with a greater proportion
of their path length (distance travelled) spent in the open arms at
some time points but not others [33,34].
Overall, there are discrepancies in behaviour of this mouse
model that could be due to gender differences, the age of testing
and the methodology used to perform the tests. Therefore we have
attempted to perform a standardised analysis of MPS IIIA mice by
first backcrossing them to the C57BL/6J background for over 10
generations and subsequently testing a cohort of MPS IIIA and
WT mice at the same circadian time point at 4, 6 and 8 months
(16, 24 and 32 weeks) of age in the 60 minute open field test, the
elevated plus maze, as well as several other neuromuscular
evaluations that we have previously shown to be effective for
phenotyping MPS IIIB mice [36]. The female MPS IIIA mice
were hyperactivity, had a recued sense of danger and no
neuromuscular differences. The open field test performed at the
same point in the circadian rhythm was a consistent, sensitive and
reliable behavioural test for the evaluation of novel therapeutic
strategies in MPS IIIA mice.
Methods
Mouse maintenance
The MPS IIIA mouse colony was maintained through
heterozygous breeding at the University of Manchester, all
procedures were ethically approved by the University of
Manchester Ethical Review Process Committee and in accordance
with the UK Home Office regulations under project licence PPL
40/3117. Mice were housed in individually ventilated cages, had
access ad libitum to food and water and were in a 12 hour light and
dark cycle. Male mice were singly housed at 14 weeks of age due to
aggressive tendencies but female mice remained housed in groups
of 4–6. The MPS IIIA mice (B6.Cg-Sgsh
mps3a) have been
backcrossed from the original mixed 129SvJ, C57BL/6, SJL,
and CD1 background [26] onto the C57BL/6J background by
more than 10 generations of backcrossing with C57BL/6J mice
(Harlan, UK) and were maintained by heterozygous breeding.
WT and MPS IIIA littermates have been used in all behavioural
experiments.
Genotyping MPS IIIA mice
M P SI I I Am i c eh a v eaGt oAm u t a t i o ni nt h eSGSH gene which
removes a Msp1I restriction enzyme digestion site. Genotyping is
performed by PCR amplification of DNA followed by Msp1I
digestion and observation of the size of DNA fragments produced.
Genomic DNA was extracted from ear punches using the GenElute
Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich) following
the manufacturer’s instructions and SGSH was amplified by PCR
using the forward primer 59 GTGTTCCCTGCCTGCTCAC 39
and reverse primer 59 CCAGTCCCCTCATCCCACTA 39.T h e
DNA was digested with Msp1I (New England Biolabs, UK) and the
DNA fragments were separated by 2% agarose gel electrophoresis.
The genotype was determined from the pattern of DNA fragments;
wild type (WT) reveals 199 bp, 118 bp and 78 bp fragments, mutant
( M U T )3 1 7 b pa n d7 8 b pf r a g m e n t sa n dh e t e r o z y g o u s( H E T )
317 bp, 199 bp, 118 bp and 78 bp.
Behavioural testing
At 4, 6 and 8 months (16, 24 and 32 weeks) of age, the same
cohorts of 10 male WT and 10 male MPS IIIA mice and 10
female WT and 11 MPS IIIA mice were analysed with the
following behavioural tests. 1.5 hours into the 12 hour light phase
the mice were dropped into the centre of an open field arena
(width 450 mm, depth 450 mm, height 500 mm) made of matt
white acrylic. The behaviour was recorded for 60 minutes using a
digital camcorder (Sony) and analysed using Top Scan software
(Clever Sys. Inc., USA). The path length, frequency (number of
times) and duration of rapid exploratory behaviour (speed
.100 mm/s), frequency and duration of immobility (speed
,5 mm/s) and frequency of entering the centre and duration in
the centre (75 mm from each edge) was analysed. Rearing in the
open field was analysed by counting the number of unsupported
rears (front paws off the floor) and supported rears (front paws on
the wall) in the first 10 minutes. The same researcher performed
all experiments and was blinded to genotype.
After a 30 minute rest, the mice were placed onto the end of an
open arm of an elevated plus maze. The maze was constructed of
matt white acrylic, comprised of four 500 mm long by 100 mm
wide arms, two of which were enclosed by 500 mm high walls, and
was raised on a stand 500 mm off the floor. Mice were placed so
they faced towards the centre of the maze and were given
10 minutes to explore the maze before returning to a cage. The
maze was cleaned using 70% ethanol. 30 minutes later the mice
were tested for a second time, in the same manner. The results
were analysed using Top Scan software (Clever Sys) to examine
the amount of time spent on the open arm, the percentage of path
length in the open arm, and the percentage of open arm entries.
30 minutes later the inverted screen test was performed, as
described previously [36]. In brief, at 4, 6 and 8 months of age the
mouse was placed on a 470 mm square with a 13 mm square wire
mesh. The screen was then rotated through 180u over 1–
2 seconds. The mouse was then suspended upside down over a
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suspended was recorded up to 2 minutes.
One hour later the horizontal bar test was performed as
described previously [14,36]. In brief, a 2 mm diameter, 300 mm
long metal wire was secured between 2 posts, 320 mm above a
padded surface. The mouse was allowed to grip the centre of the
wire and the time taken to fall or to reach the side was recorded up
to 2 minutes. The test was repeated three times as a training run
followed by a 10 minute rest before three test runs. The results
were scored as follows: crossing the bar in x seconds was scored as
240-x, remaining on the bar was scored as 120 and falling off the
bar after y seconds was recorded as y.
Urine retention
Upon sacrifice 9 male WT, 8 male MPS IIIA, 7 female WT and
8 female MPS IIIA mice at 8 months (32 weeks) of age were
dissected and the urine was removed from the bladder and volume
measured using an insulin syringe (BD).
Statistical analysis
Statistical analysis was performed using JMP software (SAS
Institute Inc, Cary, NC, USA) and analysed by MANOVA with
repeated measures for overall significances and by one or two way
ANOVA, as appropriate, with Tukey post hoc tests at individual
time points. Significance was set at p#0.05. For the MANOVA
analysis the Genotype significance determines if there is a
difference between WT and MPS IIIA mice irrespective of the
age of the mice, the Time significance determines if there is a
change in the behaviour of the mice at different ages irrespective of
the genotype and the Genotype*Time significance determines if
MPS IIIA mouse behaviour changes over time in a different
manner to WT mice.
Results
Cohorts of male and female, WT and MPS IIIA mice (n=10–
11 per group) were monitored in a 60 minute open field test as
outlined in Figure 1A. The path length minute by minute over
60 minutes is shown at 4 months (16 weeks) in Figure 1B, 6
months (24 weeks) in Figure 1C and at 8 months (32 weeks) in
Figure 1D. The behaviour in the first 3 minutes, 10 minutes and
60 minutes is presented to allow comparison against published
data and to identify the minimum amount of time required for
statistically significant analyses. At 4 months of age, female MPS
IIIA mice were significantly hyperactive and travel almost twice as
far as the WT mice over 60 minutes (p=0.037; Figure 1B).
Examining the behaviour over the first 3 minutes showed no
difference and no trend in female behaviour, but over 10 minutes
there was a non-significant trend towards hyperactivity. No
difference was found in the path length of male WT or MPS
IIIA mice at 4 months.
At 6 months of age the same female MPS IIIA mice
demonstrated increased path length with significant differences
after 10 minutes (p=0.030) and greater differences after 60 min-
utes (p=0.005; Figure 1C). No difference was detected between
male WT and MPS IIIA mice (Figure 1C).
At 8 months of age there was a trend for the female mice to be
hyperactive but no significant differences were found after 3
(p=0.73), 10 (p=0.15) or 60 minutes (p=0.18; Figure 1D).
Similarly, no significant differences were found with male mice
after 3, 10 or 60 minutes. Overall, using MANOVA repeated
measure analysis, a significant genotype difference (p=0.011),
time difference (p=1.2610
27) and a time*genotype difference
(p=0.021) were found. This indicates that overall, MPS IIIA mice
are significantly more hyperactive than WT mice, that this
changes with time and that MPS IIIA and WT mice change their
behaviour in a different manner over time.
The number of unsupported rears (front paws off the floor),
supported rears (front paws on a wall) and total rears were counted
manually in the first 10 minutes of the open field test. The only
significant change observed was a decrease in the number of
unsupported rears by female MPS IIIA mice at 6 months of age
(Figure 1F). However, given that there were no other significant
genotype effects, this may be just a chance occurrence (Figure 1E
and G). MANOVA repeated measure analysis of the data showed
no significant genotype effect in the three rearing measures, but
there was a significant decline in all measures with time
(unsupported; p=0.004, supported and total p=0.00003) irre-
spective of genotype.
Rapid exploratory motion was analysed by measuring the
frequency and duration of speed over 100 mm/s (Figure 2A–F). At
4 months of age, female MPS IIIA mice show significant increases
in both the frequency (p=0.048; Figure 2A) and duration
(p=0.05; Figure 2D) of rapid exploration over 60 minutes.
However, no significant differences were observed after 3 or
10 minutes, although a trend was detected after 10 minutes
(Figure 2A). No significant differences were found between male
MPS IIIA or WT mice at 4 months of age.
At 6 months of age, there was a trend towards increased
frequency (Figure 2B) and duration (Figure 2E) of rapid
exploratory motion after 3 minutes in the female MPS IIIA mice
(p=0.23, p=0.10). After 10 (p=0.021, p=0.034) and 60 minutes
(p=0.0003, p=0.0057), female MPS IIIA mice had significantly
increased frequency (Figure 2B) and duration (Figure 2E) of rapid
exploratory motion over 100 mm/s. No significant differences
were observed between male WT and MPS IIIA mice. This rapid
exploratory behaviour is visible in Video S1 which shows the
median female WT and MPS IIIA mouse at 6 months of age at 4
times normal speed.
At 8 months of age, female MPS IIIA mice show a trend
towards increased frequency of rapid exploratory motion over
60 minutes (p=0.18) (Figure 2C), with a trend to increase in
duration after 10 minutes (p=0.083) and a significant increase
after 60 minutes (p=0.02) (Figure 2F). Male MPS IIIA and WT
mice were indistinguishable. Using MANOVA repeated measure
analysis, there was a significant difference between WT and MPS
IIIA mice over all three time points for frequency (Genotype;
p=0.004) and duration (Genotype; p=0.013) of rapid exploratory
motion. There was a significant decline in frequency (Time;
p=9.7610
215) and duration (Time, p=4.5610
28) of rapid
exploratory motion with time and also between genotypes over
Figure 1. Open field path length and rearing. At 4, 6 and 8 months (16, 24 and 32 weeks) of age, 10 WT male (light grey squares), 10 MPS IIIA
male (dark grey squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was
recorded for 60 minutes (A). The results of the open field behaviour are presented as a 60 minute period with the average of every minute presented
and as a bar chart of the first 3 minutes, first 10 minutes and the whole hour. Error bars represent the standard error of the mean (SEM). p values were
calculated by 2 Way ANOVA. The mean average path length in Metres at 4 (B), 6 (C) and 8 (D) months have been presented. The number of
unsupported, supported and total rears in the first 10 minutes at 4 (E), 6 (F) and 8 (G) months of age have also been presented.
doi:10.1371/journal.pone.0025717.g001
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(Time*Genotype, p=0.036).
The frequency and duration the mice spent immobile was also
recorded (Figure 3A–F). There were no significant differences in
frequency of immobility between either male or female MPS IIIA
and WT mice at any time point. However, female WT mice had
significantly increased duration of immobility over 60 minutes at 4
(p=0.005) and 6 months (p=0.004) but not at 8 months
(p=0.70). Male MPS IIIA or WT mice had indistinguishable
duration of immobility at all time points measured. Using
MANOVA repeated measures there was an overall increase in
the frequency of WT immobility over MPS IIIA mice over the
three time points (Genotype; p=0.027), but no change with time
(Time; p=0.543), or genotype with time interaction (Genotype*-
Time; p=0.636). MANOVA repeated measures analysis of
duration of immobility demonstrated a significant genotype effect
over the three time points (Genotype; p=0.05), that changes
significantly with time (Time; p=1.5610
29) and changes
differently with time between the two genotypes (Genotype*Time;
p=0.030).
Mice being a prey species tend to display thigmotaxis,
remaining close to the sides of an open field arena. Increased
frequency and duration of time spent in the centre of the open
field test therefore demonstrates reduced thigmotaxis and this is
commonly considered to be a measure of reduced anxiety or
reduced sense of danger that the animal experiences [37]. Male
MPS IIIA and WT mice showed no significant differences in
frequency of centre entries at any age (Figure 4A, B and C). At 4
months of age, female MPS IIIA mice showed significantly
increased centre entries at 60 minutes (p=0.0045). At 6 months
female MPS IIIA mice entered the centre significantly more at 3,
10 and 60 minutes (p=0.057, p=0.023, p=0.0005; Figure 4B).
At 8 months of age female MPS IIIA showed no significant
increases in centre entries (p=0.37)(Figure 4C). Using MANOVA
MPS IIIA mice showed significantly increased centre entries
(Genotype; p=0.003), which changed significantly over time
(Time; p=2.3610
211) and between genotypes over time (Geno-
type*Time; p=0.0013).
The duration spent in the centre has also been analysed. At 4
months of age, female MPS IIIA mice spent significantly more
time in the centre than WT, after 60 minutes (p=0.012;
Figure 4D). Males were not significantly different. At 6 months
of age female MPS IIIA mice had increase duration in the centre
after 60 minutes (p=0.012) and showed an almost significant
trend in male mice (p=0.055; Figure 4E). At 8 months of age
there are no significant differences between genotypes (Figure 4F).
By MANOVA repeated measure analysis MPS IIIA mice spend
significantly increased duration in the centre area (Genotype;
p=0.001), this changes significantly over time (Time;
p=2.5610
26) and between genotypes over time (Time*Genotype;
p=0.005).
Thirty minutes after behavioural analysis in the open field, the
same cohort of mice were tested on an elevated plus maze
(Figure 5A) for ten minutes, followed by a 30 minute rest and
another 10 minute trial. Several parameters were measured
(frequency of entering open arm, percentage of entries into the
open arm, path length in open arm, percentage of path length in
open arm and time in open arm) but none reached significance.
Here we have presented the percentage of entries to the open
arms, percentage of path length in the open arms and duration in
the open arms as measure of anxiety (Figure 5B, C, D), which is
representative of many of the other measures. At 4, 6 and 8
months of age there was no significant difference in male or female
WT or MPS IIIA open arm entries (Figure 5B, C, D). At 4, 6 and
8 months there was no difference between WT and MPS IIIA
mice in the repeat elevated plus maze and no difference between
first and second elevated plus maze tests except that in the second
test, all the mice performed fewer entries and had a shorter path
length (Figure S1A–C). Statistical analysis by MANOVA showed
no significant difference in genotype, or time but there was a
significant difference in how the genotypes behaved over time in
the percentage of path length in the open arm (p=0.019) as the
MPS IIIA mouse path length decreased at 8 months but the WT
increased.
The inverted screen test (Figure 6A) and horizontal bar crossing
test (Figure 6B) were also performed. The inverted screen test
measures neuromuscular strength and the bar crossing test
measures both neuromuscular strength and motor coordination.
The bar crossing test showed no significant differences between
WT and MPS IIIA of either sex at 4, 6 or 8 months of age
(Figure 6C–E). Over time, there was a significant decrease in the
number of moves and time spent on the inverted screen
(p=1.7610
26, p=1.2610
25), and a significant sex difference in
the number of moves with females moving more (p=0.004). Bar
crossing showed no genotype effect and no time effect but there
was a significant Time*Sex effect (p=0.044), as the female score
decreased over time but the male score increased at 6 months and
then decreased at 8 months.
Discussion
We have backcrossed the mixed background MPS IIIA mouse
model onto the C57BL/6J background and characterised a
behavioural phenotype that can be used to accurately distinguish
female MPS IIIA mice from WT littermates. Our findings clearly
show that male mice show no significant difference to WT
littermates in the open field test or elevated plus maze, whilst
female MPS IIIA mice demonstrate characteristic hyperactive
behaviour initially at 4 months (16 weeks) and more strongly at 6
months (24 weeks), which declines again at 8 months (32 weeks) of
age. We also show that these mice have a reduced thigmotaxis at 4
and 6 months of age which would indicate a reduced sense of
danger. Hyperactivity and a reduced sense of danger are observed
in the behavioural phenotype of the MPS IIIA patients
[1,7,10,11].
In this study we observed no significant behavioural differences
between WT and MPS IIIA male mice. This is in contrast to
Hemsley et al. 2005 where hyperactivity was initially observed at 3
weeks, hypoactivity at 6 and 15 weeks and no changes at 10, 20
and 40 weeks in male mixed background mice [32]. Lau et al. 2008
used male MPS IIIA mice that had been back crossed onto the
C57BL/6 background and observed no differences at 3, 5 and 15
Figure 2. Open field rapid exploratory behaviour. At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey
squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was recorded for
60 minutes. The results of this test are presented as a 60 minute period with the average of every minute presented and as a bar chart of the first
3 minutes, first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 Way ANOVA. The frequency of moving
faster than 100 mm/s at 4 (A), 6 (B) and 8 (C) months and the duration spent moving faster than 100 mm/s at 4 (D), 6 (E) and 8 (F) months of age have
been presented.
doi:10.1371/journal.pone.0025717.g002
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but subsequently observed hypoactivity in 15 week old male mice
[22]. Crawley et al., using male MPS IIIA mice on the same
C57BL/6 background, found no changes at 4, 6, 8, 10, 15, 18, 22,
25, 32 and 40 weeks and only observed hyperactivity at 12 weeks
[30]. Finally, using male mice independently crossed onto the
C57BL/6J background by Jackson laboratories, hypoactivity was
observed in MPS IIIA mice at 20 weeks of age by McIntyre et al.
but no difference was found at 24 or 32 weeks [38]. Clearly, it is
hard to obtain consistent behavioural readouts from male mice in
this context and it is always difficult to know if hypoactivity could
be confounded by any parameter affecting the mouse’s physical
ability to move. We find male MPS IIIA mice to be very aggressive
and are unable to keep them group housed, which is likely to
change their behaviour. Singly housing male C57BL/6 mice has
been shown to increase locomotor activity and reduce anxiety [39]
or alternatively in other researchers hands to have no effect [40].
At the very least, it certainly leads to weight gains, which will
restrict movement, and this may confound reliable open field
measures. Additionally we find that all MPS IIIA mice retain urine
over time, with male mice retaining significantly more urine at 8
months of age and urine retention is the humane endpoint (Figure
S2). Clearly urinary retention could be restricting movement
which would confound behavioural measures. Lastly, it is worth
pointing out that many male mouse studies are on mixed, C57BL/
6 or C57BL/6J backgrounds, some of which have been performed
in different laboratories, which could lead to inconsistencies in
outcomes. Overall, we would argue that comparisons of male MPS
IIIA mice with WT are not appropriate (or easy to perform) for
determination of treatment responses.
Several studies analysed behaviour of male MPS IIIA mice
following control intracranial injections. Fraldi et al. tested male
mice and found that the MPS IIIA mice were hyperactive at 21
weeks of age but not prior to this, but these mice had received
intracranial injections and this may have adversely affected the
mouse’s behaviour [23]. Other studies where intracranial
injections have been given to MPS IIIA mice all used male mice
and generally observed either no changes or hypoactivity
[18,21,35]. It is worth considering that intracranial injections
could have altered the natural behaviour of the mouse and this
may be why hypoactivity is observed.
We found female MPS IIIA mice to be hyperactive, having a
significantly increased path length, frequency and duration of
rapid exploratory behaviour and reduced duration of immobility
at 4 and 6 months of age, (16 and 24 weeks) whilst duration of
rapid exploratory behaviour was significantly increased at 8
months (32 weeks). At 4 months of age differences are only
significant after 60 minutes, but at 6 months they are all significant
after both 10 and 60 minutes. This indicates that the 60 minute
test is a more sensitive test to identify hyperactivity than the 10 or
3 minutes tests. No significant differences were observed over the
first 3 minutes at any time point, thus we would suggest that
studies such as that of Crawley et al. 2006 where this short test has
been used are not likely to yield significant differences [30].
Our hyperactivity findings in females are supported by Crawley
et al, where hyperactivity was observed at 22 and 32 weeks of age
in a 3 minute test with female MPS IIIA C57BL/6 mice, however
no difference was observed at any point prior to 18 weeks or at 25
or 40 weeks of age [30]. They also observed hypoactivity in
females at 4 weeks of age but we do not have comparative data to
comment on this. The longer testing time utilised in our study may
have meant that we were better able to detect behavioural changes
in the mice that were not detectable with the 3 minute test.
On the mixed background, female MPS IIIA mice were
hyperactive at 3 weeks of age but at subsequent ages no differences
were observed at 6, 10, 15, 20, 30 or 40 weeks of age [32]. In the
work of Lau et al., using the C57BL/6 backcross, no differences
were observed between female WT and MPS IIIA C57BL/6 mice
between 3–22 weeks of age [33].
MPS IIIB is a phenotypically indistinguishable disease to MPS
IIIA. In the mouse model of MPS IIIB, hyperactivity has been
observed in a 10 minute open field test [41] but hypoactivity in an
8 minute open field test performed half in the light half in the dark
[42]. A 60 minute open field test did not report differences in path
length in male or female mice [43], but a 60 minute open field test
that we performed on female mice at the same circadian time as
this study observed hyperactivity at 8 months of age [36], which is
consistent with our findings here. We also observed significant
increases in hyperactivity in male MPS IIIB mice at 8 months of
age, although they were less significant differences than those
observed in females [14]. The MPS IIIB mouse is a complete
knockout and thus may be slightly more severe than the MPS IIIA
mouse with ,3% residual enzyme activity. This may explain why
we were able to detect significant genotype differences at 8 months
of age in MPS IIIB in all parameters but only some in MPS IIIA.
We believe that the 60 minute open field test is still measuring
habituation behaviour due to the profiles of activity observed in
both MPSIIIA mice in this paper and in MPSIIIB mice [36] over
time. We found that differences in behaviour between MPS IIIB
and WT mice [36] and MPS IIIA and WT mice (Figure 1B and C)
became more pronounced from 3 to 10 to 60 minutes and
diverged in the first few minutes from a similar initial response.
When we compared MPS IIIB and WT mice over a 24 hour
period following 24 hours of habituation [36] the differences were
significantly muted and over 14 days there was no significant
difference [44]. This suggests that a 60 minute open field test does
not reflect home cage behaviour but instead probably measures
extended habituation to a novel environment.
A significant decrease in the number of unsupported rears by
female MPS IIIA mice was observed at 6 months of age, however,
there was no difference in the overall number of rears, or
supported rears, at this or any other time point. No consistent
trend in the number of rears with female mice is apparent in the
literature, Crawley et al. reported that female MPS IIIA mice
reared less at 15 and 25 weeks of age but there were no significant
differences at 9 other time points [30]. No significant differences in
rearing were observed in Lau et al. who also used backcrossed mice
[33], or Hemsley et al who used mixed background mice [32]. A
more consistent trend is observed in male mice with MPS IIIA
rearing less [18,30,32,33,35], but increased rearing has been
observed at 3 weeks [32]. However, at most time points no
significant difference is observed. Manual measurement of rears
Figure 3. Open field immobile behaviour. At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey squares), 10
WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was recorded for 60 minutes. The
results of this test are presented as a 60 minute period with the average of every minute presented and as a bar chart of the first 3 minutes, first
10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 Way ANOVA. The frequency of not moving at 4 (A), 6 (B)
and 8 (C) months and the duration spent not moving at 4 (D), 6 (E) and 8 (F) months of age have been presented.
doi:10.1371/journal.pone.0025717.g003
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behaviour, such as amount of time per rear that cannot be
measured by simply counting the number of rears. This is why we
examined the number of supported and unsupported rears
[36,45]. In the MPS IIIB mouse model, no difference in rearing
was observed in the first 10 minutes of an open field test with
female mice at 8 months of age [36] and no difference in the first
30 minutes but a significant decrease in the number of rears by
4.5–5 month old male MPS IIIB mice in the second 30 minutes of
a 60 minute open field test [43]. Our conclusion is that rearing is
too variable an outcome in MPS IIIA and IIIB mice and is
therefore not a valuable informative test.
At 4 and 6 months of age the MPS IIIA female mice had a
reduced sense of danger and spent a greater proportion of time in
Figure 4. Open field sense of danger behaviour. At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey
squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was recorded for
60 minutes. The results of this test are presented as a 60 minute period with the average of every minute presented and as a bar chart of the first
3 minutes, first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 Way ANOVA. The frequency of entering
the centre at 4 (A), 6 (B) and 8 (C) months and the duration spent in the centre at 4 (D), 6 (E) and 8 (F) months of age have been presented.
doi:10.1371/journal.pone.0025717.g004
Figure 5. Elevated plus maze behaviour. At 4, 6 and 8 months of age 7–11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT female
(white bars) and MPS IIIA female (black bars) were placed on the elevated plus maze (A) and the behaviour was recorded for 10 minutes. After a
30 minute rest, the test was repeated. The results of the first test are presented as the mean of each measure with error bars representing the SEM. p
values were calculated by 2 Way ANOVA. The following measures have been presented; the percentage of total entries that were into the open arm,
the percentage of the path length in the open arm and the duration spent on the open arm at 4 (B), 6 (C) and 8 (D) months of age.
doi:10.1371/journal.pone.0025717.g005
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60 minutes but not after 3 or 10 minutes. This is supported by the
patients with MPS IIIA which are believed to have a reduced sense
of danger [1]. No difference in the time in centre was detected by
Lau et al. in both male and female mice [33], however this could be
because the open field was larger in our study and therefore more
sensitive to thigmotaxis [45,46]. In the MPS IIIB mouse model no
differences were observed in the duration spent in the centre of the
open field [36] but the open field used in that study was also
smaller than the one used in this study.
The elevated plus maze did not demonstrate a decrease in
anxiety or sense of danger in the MPS IIIA mice. There were also
no differences between repeat tests, and both WT and MPS IIIA
mice appeared to habituate equally. Lau et al. 2010, observed no
significant differences with male mice at 6.5 months (26 weeks) of
age with a 5 minute elevated plus maze test, but there was a trend
towards reduced anxiety [34]. However in Lau et al. 2008 a
significant increase in the time the male MPS IIIA mice spent in
the open arms at 18 weeks of age, the percentage of the path
length on the open arms at 15 and 18 weeks and the percentage of
entries into the open arms at 20 weeks was observed [33].
Additionally they observed significant differences between repeats
of the elevated plus maze, male MPS IIIA mice had a significantly
longer path length in the repeat elevated plus maze test while WT
mice remained unchanged [33]. We did not observe decreased
anxiety or a change in behaviour between repeat elevated plus
maze tests. The width of the arms could be affecting this test as this
study used 10 cm wide arms and Lau et al., used 7 cm wide arms.
It has been demonstrated that when using 5, 7 or 9 cm wide arms,
NMRI mice spent more time in the wider open arms compared to
C57BL/10J mice that showed no difference [47]. Ten minutes on
the elevated plus maze may also be too short a time to detect the
sense of danger differences in the MPS IIIA mice as the only
centre measure on open field that is significant after 10 minutes is
Figure 6. Neuromuscular behaviour. At 4, 6 and 8 months of age 8–11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT female (white
bars) and MPS IIIA female (black bars) were placed on the inverted screen test (A) and horizontal bar crossing test (B). The number of rear leg moves,
the time spent on the inverted screen and the bar crossing score are presented at 4 (C), 6 (D) and 8 (E) moths of age. Error bars represent the SEM and
p values were calculated by 2 Way ANOVA.
doi:10.1371/journal.pone.0025717.g006
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(p=0.023). A lack of difference in the elevated plus maze
performed in daylight is supported by MPS IIIB mice which
showed no difference in the light but were less anxious in the dark
[41]. The increased number of centre entries and duration in the
open field could perhaps reflect increased but undirected anxiety
whereby mice are actually more agitated but have lost the ability
to determine what is dangerous. A more pragmatic explanation
could be due to the mice not being naively tested as they only
received a 30 minute break after the open field test before starting
the elevated plus maze test. Prior behavioural tests can affect the
result of elevated plus maze tests with C57BL/6J mice that have
previously been tested in an open field test [48].
No significant differences were observed in the inverted screen
or bar crossing tests which is consistent with the work of Crawley et
al. who observed no difference in neuromuscular strength with
back crossed MPS IIIA mice [30]. However on the mixed
background strain, there was a significant decrease in neuromus-
cular strength with MPS IIIA mice being unable to grip the
inverted screen for as long as the WT mice from 20 weeks of age
[32]. The work in our study is supported by work with the MPS
IIIB mouse model that does not show a decline in motor function
at 5 months of age by accelerating rotarod [43,49] but does by a
rocking rotarod test from 9 months onwards [50,51]. The decline
in motor function could relate to the presence of increasing urine
retention in the MPS IIIA and B mouse models [14,26,29]. Our
own tests in the MPS IIIB mouse model found that neuromuscular
decline only occurred at 10 months of age (40 weeks) [14,36].
Given that the MPS IIIA mouse has residual enzyme activity, it is
possible that progression of MPS IIIA disease is slightly less rapid
than in MPS IIIB which would explain why we did not see a trend
to changes in motor function at 8 months in MPS IIIA mice.
Standardisation of tests is a very important aspect of
behavioural test design that may have affected comparison of
our tests to those of other laboratories. In this study the size of the
open field was larger than that described in many studies and the
behaviour was observed for much longer (60 minutes compared to
3 minutes). The increased size and time of the test allows better
spatial and temporal resolution of the mouse behaviour and so
makes the test more sensitive [45]. Video analysis software was
used which has been shown to be more sensitive than line crossing
determined by an observer or beam breaks [52]. In this study, the
mouse was placed in the centre of the open field rather than in the
corner and the test was carried out at the same time point of
circadian rhythm for all mice as there is a known peak in activity
in the similar MPS IIIB mouse model [44]. The mice in this study
were also housed differently; females were group housed and male
mice were singly housed from 14 weeks of age. The background of
the mice can affect the behavioural phenotype, therefore we
backcrossed the MPS IIIA mice in this study onto the C57BL/6J
background for more than 10 generations. Other groups have
used MPS IIIA mice on a mixed background [18,32], or on a
C57BL/6 [23,30,33,34] or C57BL/6J [21] background. Strain
specific differences can also significantly affect behavioural
outcomes [53].
Conclusion
We have demonstrated that we can reliably detect differences in
the behaviour of female but not male MPS IIIA mice at 4 and 6
months (16 and 24 weeks) of age and these differences match the
patient phenotype. Male mice were singly housed due to their
aggression which may change comparative behavioural responses.
Female MPS IIIA mice are hyperactive, with a longer path length,
increased frequency and duration of rapid exploratory behaviour,
and spend less time immobile. They also show a trend to this
behaviour at 8 months of age with significantly increased duration
of rapid exploratory behaviour. Female MPS IIIA mice demon-
strate a reduced sense of danger with a greater proportion of the
time spent in the centre of the open field with a greater number of
centre entries. These two time points and multiple measures are
ideal to evaluate novel therapies for MPS IIIA as the effect of a
therapy can be sensitively determined using multiple measures.
This behavioural phenotype is supported by both the phenotype of
the patients and our recent similar observations in the MPS IIIB
mouse model [14,36]. The increased size of the open field, the
increased length of the test, the use of video analysis software and
performing the test at consistent point in the circadian rhythm
have produced a sensitive and robust test to evaluate the effect of
therapies on female MPS IIIA mice.
Supporting Information
Figure S1 Repeat elevated plus maze behaviour. At 4, 6
and 8 months of age 7–11 WT male (light grey bars), MPS IIIA
male (dark grey bars), WT female (white bars) and MPS IIIA
female (black bars) were placed on the elevated plus maze (A) and
the behaviour was recorded for 10 minutes. After a 30 minute
rest, the test was repeated. The results of the repeat test are
presented as the mean of each measure with error bars
representing the SEM. p values were calculated by 2 Way
ANOVA. The following measures have been presented; the
percentage of total entries that were into the open arm, the
percentage of the path length in the open arm and the duration
spent on the open arm at 4 (A), 6 (B) and 8 (C) months of age.
(TIF)
Figure S2 Urine retention at 8 months. At 8 months of age
9 WT male (light grey bars), 8 MPS IIIA male (dark grey bars), 7
WT female (white bars) and 8 MPS IIIA female (black bars) were
sacrificed and the urine volume in the bladder measured. The
results are presented as the mean with error bars representing the
SEM. p values were calculated by 2 Way ANOVA.
(TIF)
Video S1 Open field behaviour video. A video running at 4
times the normal speed showing the median female WT and MPS
IIIA mouse at 6 months of age. The MPS IIIA mouse is on the left
and the WT mouse is on the right.
(WMV)
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